Zacks Investment Research upgraded shares of Concordia International (NASDAQ:CXRX) (TSE:CXR) from a sell rating to a hold rating in a research report sent to investors on Friday morning.
According to Zacks, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada. “
Separately, ValuEngine upgraded Concordia International from a hold rating to a buy rating in a research report on Friday, December 1st.
An institutional investor recently raised its position in Concordia International stock. Renaissance Technologies LLC raised its holdings in Concordia International Corp (NASDAQ:CXRX) (TSE:CXR) by 196.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 455,983 shares of the company’s stock after purchasing an additional 302,284 shares during the quarter. Renaissance Technologies LLC owned 0.89% of Concordia International worth $300,000 as of its most recent SEC filing. 7.04% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Concordia International (CXRX) Upgraded to “Hold” at Zacks Investment Research” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3258596/concordia-international-cxrx-upgraded-to-hold-at-zacks-investment-research.html.
Concordia International Company Profile
Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Concordia International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia International and related companies with MarketBeat.com's FREE daily email newsletter.